Ptc Therapeutics (PTCT) EBITDA (2012 - 2026)

Ptc Therapeutics' EBITDA history runs 15 years deep, the most recent figure standing at $45.0 million for Q1 2026.

• In Q1 2026, EBITDA fell 95.37% year-over-year to $45.0 million; the TTM figure through Mar 2026 stood at -$58.3 million (down 108.18% YoY), while the FY2025 annual figure was $866.9 million, up 386.52% from the prior year.
• EBITDA was $45.0 million for Q1 2026 at Ptc Therapeutics, up from -$71.3 million in the prior quarter.
• In the past five years, EBITDA ranged from a high of $970.2 million in Q1 2025 to a low of -$209.5 million in Q2 2023.
• Historically, EBITDA has averaged -$16.3 million across 5 years, with a median of -$68.2 million in 2022.
• The sharpest annual moves came in 2024 and 2025: EBITDA plunged 2890.19% in 2024, then jumped 2234.57% in 2025.
• A 5-year view of EBITDA shows it stood at -$200.3 million in 2022, then jumped by 102.91% to $5.8 million in 2023, then slumped by 2890.19% to -$162.4 million in 2024, then surged by 56.06% to -$71.3 million in 2025, then soared by 163.01% to $45.0 million in 2026.
• The last three EBITDA figures came in at $45.0 million (Q1 2026), -$71.3 million (Q4 2025), and $3.0 million (Q3 2025), per Business Quant data.